Tampere, Finland — Founded in 2015 in Tampere, Finland, Neuro Event Labs is a leading AI Motion Diagnostics and Digital Health company.
In a recent development, Neuro Event Labs announced a strategy change toward worldwide development with the appointment of Rodney (Rod) J. Williams as Chief Executive Officer of Neuro Event Labs, Inc., the company’s U.S. subsidiary.
Nelli® is commercially available in the EU and has been granted Breakthrough Device Designation by the FDA. A 510(k) marketing application is in review by the US FDA. Use is limited by Federal (or the United States) law as an investigational use. Nelli® system combines video-based automated seizure detection with an artificial intelligence-based algorithm that automatically classifies seizure type. The combination of AI and human expertise, without EEG, is revolutionary.
The newly appointed CEO of NEL Inc., Rod Williams, has extensive commercialization, strategy, and market access planning experience in developing new markets. He has held a number of senior management positions at world-class healthcare companies, including Johnson & Johnson, General Electric, Align Technology, and most recently, as President and CEO of PaceMate. His prior managerial positions and commercialization abilities have equipped him well to expand Neuro Event Labs, Inc. to become a market leader in digital health.
Kaapo Annala, Founder and CEO of Neuro Event Labs, said, “Rod’s breadth of executive leadership across various sectors has provided him with the capability to efficiently scale organizations while leaning on his diverse industry experience to accelerate the adoption of transformative digital technologies that solve legacy problems while improving patient care,”
He further added, “Bringing that particular expertise to Neuro Event Labs, Inc. will allow us to establish a new standard for smart seizure detection and epilepsy monitoring as a company, while differentiating from our competitors.”
Williams thinks Nelli® has a bright future and is synergistic with innovative new products he has helped commercialize that have improved patient care. He told the press, “I am pleased to be joining Neuro Event Labs and its tremendously inventive team at this vital time in the company’s evolution as it expands its business in the United States of America. The Nelli® platform puts us in a leading position to help neurologists enhance patient care by analyzing digital data driven by AI.”
In its quest to become the go-to service for AI Motion Diagnostics, Neuro Event Labs is at the frontline of this movement, developing and deploying first-of-its-kind cloud-based neuro-centric software, digital technology, and AI solutions. In response to Rod’s appointment as CEO, Kaapo comments, “We are thrilled that Rod will be heading this crucial new effort for Neuro Event Labs, Inc. and look forward to the ongoing growth and acceptance of the Nelli® service under his direction.”
About Neuro Event Labs
Neuro Event Labs (NEL) is an epilepsy monitoring firm with its headquarters in Tampere, Finland. It has won several accolades and awards. Nelli® is the revolutionary technology that NEL has developed, which is a cloud-based neuro-centric software package that also includes artificial intelligence technologies and service solutions. The company is committed to making a positive difference in the lives of patients by providing monitoring solutions and services that are user-friendly, of excellent quality, and reasonably priced. Its purpose is to provide neurologists with the most recent developments and advancements in the field of epilepsy research, thus enabling treatment regimens that are based on a new standard for objectively monitoring the outcomes of epileptic treatments.
For more information concerning Neuro Event Labs and its technology, please visit www.neuroeventlabs.com or follow on LinkedIn, Twitter and Facebook.
Company Name: Neuro Event Labs
Contact Person : Dr. Aisyah Jamil
Email : email@example.com
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Mutual Funds journalist was involved in the writing and production of this article.